Therefore, we used PI3K inhibitor GDC-0941 [47] and AKT activator SC-79 [48] to conduct rescue experiments in vitro as well as in vivo, in which we noticed that the PI3K-Akt pathway activator can abolish or decrease the effect of inhibiting tumor progression after LETM2 knockdown. This evidence concerns the gene LETM2 and neoplasm.